Brief: Antengene Announces Clinical Trial Collaboration With Beigene To Evaluate Selinexor In Combination With Tislelizumab In T And Nk-Cell Lymphoma
27/06/2022 01:41
June 26 (Reuters) - Antengene Corporation Ltd 6996.HK :
* ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH
BEIGENE TO
EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND
NK-CELL LYMPHOMA
Source text for Eikon: ID:nPnbwqm6sa
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106